预约演示

更新于：2025-05-07

HLA-G

更新于：2025-05-07

基本信息

别名

HLA class I histocompatibility antigen, alpha chain G、HLA G antigen、HLA-6.0

+ [6]

简介

Non-classical major histocompatibility class Ib molecule involved in immune regulatory processes at the maternal-fetal interface (PubMed:19304799, PubMed:23184984, PubMed:29262349). In complex with B2M/beta-2 microglobulin binds a limited repertoire of nonamer self-peptides derived from intracellular proteins including histones and ribosomal proteins (PubMed:7584149, PubMed:8805247). Peptide-bound HLA-G-B2M complex acts as a ligand for inhibitory/activating KIR2DL4, LILRB1 and LILRB2 receptors on uterine immune cells to promote fetal development while maintaining maternal-fetal tolerance (PubMed:16366734, PubMed:19304799, PubMed:20448110, PubMed:23184984, PubMed:27859042, PubMed:29262349). Upon interaction with KIR2DL4 and LILRB1 receptors on decidual NK cells, it triggers NK cell senescence-associated secretory phenotype as a molecular switch to promote vascular remodeling and fetal growth in early pregnancy (PubMed:16366734, PubMed:19304799, PubMed:23184984, PubMed:29262349). Through interaction with KIR2DL4 receptor on decidual macrophages induces pro-inflammatory cytokine production mainly associated with tissue remodeling (PubMed:19304799). Through interaction with LILRB2 receptor triggers differentiation of type 1 regulatory T cells and myeloid-derived suppressor cells, both of which actively maintain maternal-fetal tolerance (PubMed:20448110, PubMed:27859042). May play a role in balancing tolerance and antiviral-immunity at maternal-fetal interface by keeping in check the effector functions of NK, CD8+ T cells and B cells (PubMed:10190900, PubMed:11290782, PubMed:24453251). Reprograms B cells toward an immune suppressive phenotype via LILRB1 (PubMed:24453251). May induce immune activation/suppression via intercellular membrane transfer (trogocytosis), likely enabling interaction with KIR2DL4, which resides mostly in endosomes (PubMed:20179272, PubMed:26460007). Through interaction with the inhibitory receptor CD160 on endothelial cells may control angiogenesis in immune privileged sites (PubMed:16809620). Likely does not bind B2M and presents peptides. Negatively regulates NK cell- and CD8+ T cell-mediated cytotoxicity (PubMed:11290782). Likely does not bind B2M and presents peptides. Negatively regulates NK cell- and CD8+ T cell-mediated cytotoxicity (PubMed:11290782). Likely does not bind B2M and presents peptides. Negatively regulates NK cell- and CD8+ T cell-mediated cytotoxicity (PubMed:11290782). Non-classical major histocompatibility class Ib molecule involved in immune regulatory processes at the maternal-fetal interface (PubMed:19304799, PubMed:23184984, PubMed:29262349). In complex with B2M/beta-2 microglobulin binds a limited repertoire of nonamer self-peptides derived from intracellular proteins including histones and ribosomal proteins (PubMed:7584149, PubMed:8805247). Peptide-bound HLA-G-B2M complex acts as a ligand for inhibitory/activating KIR2DL4, LILRB1 and LILRB2 receptors on uterine immune cells to promote fetal development while maintaining maternal-fetal tolerance (PubMed:16366734, PubMed:19304799, PubMed:20448110, PubMed:23184984, PubMed:29262349). Upon interaction with KIR2DL4 and LILRB1 receptors on decidual NK cells, it triggers NK cell senescence-associated secretory phenotype as a molecular switch to promote vascular remodeling and fetal growth in early pregnancy (PubMed:16366734, PubMed:19304799, PubMed:23184984, PubMed:29262349). Through interaction with KIR2DL4 receptor on decidual macrophages induces pro-inflammatory cytokine production mainly associated with tissue remodeling (PubMed:19304799). Through interaction with LILRB2 receptor triggers differentiation of type 1 regulatory T cells and myeloid-derived suppressor cells, both of which actively maintain maternal-fetal tolerance (PubMed:20448110). Reprograms B cells toward an immune suppressive phenotype via LILRB1 (PubMed:24453251). Likely does not bind B2M and presents peptides. Likely does not bind B2M and presents peptides.

关联

项与 HLA-G 相关的药物

IVS-3001

靶点

HLA-G

作用机制

HLA-G调节剂

在研机构

Invectys, Inc. [+1]

原研机构

Invectys, Inc

在研适应症

局部晚期恶性实体瘤 [+7]

非在研适应症-

最高研发阶段临床1/2期

首次获批国家/地区-

首次获批日期1800-01-20

TTX-080

靶点

HLA-G

作用机制

HLA-G抑制剂 [+1]

在研机构

Tizona Therapeutics, Inc.

原研机构

Tizona Therapeutics, Inc.

在研适应症

肢端雀斑恶性黑色素瘤 [+8]

非在研适应症-

最高研发阶段临床1期

首次获批国家/地区-

首次获批日期1800-01-20

JNJ-78306358

靶点

CD3 x HLA-G

作用机制

CD3刺激剂 [+1]

在研机构

Janssen Research & Development LLC

原研机构

Janssen Research & Development LLC

在研适应症

晚期恶性实体瘤

非在研适应症-

最高研发阶段临床1期

首次获批国家/地区-

首次获批日期1800-01-20

项与 HLA-G 相关的临床试验

NCT05672459

/ Recruiting临床1/2期IIT

A Phase 1/2a, Safety And Efficacy Study Of HLA-G- Targeted CAR-T Cells IVS-3001 In Subjects With Previously Treated Advanced HLA-G-Positive Solid Tumors

The proposed clinical study is a Phase 1/2a trial to investigate the safety, tolerability, pharmacokinetics and clinical activity of anti-HLA-G CAR-T cells IVS-3001 administered to subjects with previously treated, locally advanced, or metastatic solid tumors which are HLA-G positive (HLA-G+) - as determined by immunohistochemistry (IHC) analysis on tumor biopsies using the 4H84 antibody.

开始日期2023-06-21

申办/合作机构

The University of Texas MD Anderson Cancer Center

[+1]

NCT05769959

/ Terminated临床1期

An Open-Label, Multicenter, Phase 1 Study to Evaluate Safety, Pharmacokinetics, and Preliminary Anti-Tumor Activity of RO7515629 in Participants With Unresectable and/or Metastatic HLA-G Positive Solid Tumors

The main purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, immune response and preliminary anti-tumor activity of RO7515629 alone in participants with advanced or metastatic solid tumors expressing human leukocyte antigen G (HLA-G).

开始日期2023-06-15

申办/合作机构

Roche Holding AG

NCT04991740

/ Completed临床1期

A Phase 1 Study of JNJ-78306358, a T Cell Redirecting Bispecific Antibody Targeting HLA-G for Advanced Stage Solid Tumors

The purpose of this study is to determine the recommended phase 2 dose (RP2D) regimen(s) of JNJ-78306358 in Part 1 (Dose Escalation) and to determine the safety of JNJ-78306358 at the RP2D regimen(s) in Part 2 (Dose Expansion).

开始日期2021-10-24

申办/合作机构

Janssen Research & Development LLC

100 项与 HLA-G 相关的临床结果

登录后查看更多信息

100 项与 HLA-G 相关的转化医学

登录后查看更多信息

0 项与 HLA-G 相关的专利（医药）

登录后查看更多信息

2,653

项与 HLA-G 相关的文献（医药）

2025-12-01·Histochemistry and Cell Biology

Replicative senescence in amniotic fluid-derived mesenchymal stem cells and its impact on their immunomodulatory properties

Article

作者: Javid, Amane ; Javazm, Reza Rafiei ; Abessi, Panteha ; Zare, Elham ; Azad, Faezeh Sadat ; Hoseini, Seyed Mehdi ; Hosseini, Elham Sadat ; Montazeri, Fateme

The expansion of mesenchymal stem cells (MSCs) for clinical applications is often limited by replicative senescence, a growth arrest induced by various stresses during in vitro culture, yet its impact on the immunomodulatory properties of MSCs remains unclear. This study derived MSCs from the amniotic fluid (AF-MSCs) of seven first-trimester pregnancies, characterized them through flow cytometry, and evaluated their osteogenic differentiation potential before expanding the cells to compare immunoregulatory gene expression in proliferative and senescent states. Additionally, an assessment of the adipogenic differentiation potential of AF-MSCs from three samples was conducted following their recovery from approximately 9 months of cryopreservation, with results showing that these recovered cells retain the capacity for adipogenic differentiation. Molecular analysis revealed no significant differences in the expression of key immunoregulatory genes, such as TGFβ, IL-10, IDO, and VCAM-1, between proliferative and senescent cells, although senescent cells showed downregulation of FASL and upregulation of IL-6, COX1, and HLA-G. Markers of cell proliferation, including FOXM1 and B-MYB, were significantly downregulated in senescent cells, confirming the progression of replicative senescence. Despite expectations, the results indicated that some immunomodulatory markers remained stable or were even enhanced in senescent AF-MSCs. These findings highlight the resilience of AF-MSC immunomodulatory properties during prolonged in vitro expansion, supporting their potential for therapeutic applications despite the challenges posed by replicative senescence.

2025-06-01·Journal of Bone Oncology

Decoding the immune landscape in Ewing sarcoma pathogenesis: The role of tumor infiltrating immune cells and immune milieu

Review

作者: Gorain, Jaya Kanta ; Rahul, Ekta ; Ganguly, Shuvadeep ; Bakhshi, Sameer ; Sharma, Uttam ; Agarwal, Nikita ; Shree, Akshi ; Kumar, Rajiv Ranjan

Ewing sarcoma (EwS) is the second most prevalent pediatric bone malignancy, characterized by its aggressive behavior and unfavorable prognosis. The tumor microenvironment (TME) of EwS is shaped by immunosuppressive components, including myeloid-derived suppressor cells, tumor-associated macrophages, and immune checkpoint molecules such as PD-1/PD-L1 and HLA-G. These elements impair anti-tumor immune responses by modulating the function of tumor-infiltrating immune cells, such as regulatory T cells (Tregs), CD8⁺ T cells, and natural killer cells. Chemokines, including CXCL9 and CXCL12, and cytokines, such as transforming growth factor-beta and interleukin-10, further contribute to immune suppression and promote metastatic dissemination. Recent advances in immunotherapy have highlighted the therapeutic potential of modulating immune cells and signaling pathways to enhance anti-tumor immunity. This review provides a comprehensive analysis of the complex immune landscape within the EwS TME, focusing on the mechanistic roles of key immune components and their potential as therapeutic targets. Understanding these interactions could pave the way for innovative treatment strategies to improve clinical outcomes in patients with EwS.

2025-05-01·Human Immunology

Decoding immune tolerance in infertility: Exploring immune pathways and non-coding RNAs as pioneering biomarkers and therapeutic targets

Review

作者: Mustafa, Yasser Fakri ; Khaleel, Abdulrahman Qais ; Kadhum, Wesam R ; Mohammed, Saad Khudhur ; Pramanik, Atreyi ; Kumar, Ashwani ; Hjazi, Ahmed ; Pallathadka, Harikumar ; Aloraibi, Farah ; Hamzah, Hamza Fadhel

Infertility, impacting a significant number of couples, is characterized by the failure to conceive after one year of consistent, unprotected sexual intercourse. It is multifactorial, with etiological contributors including ovulatory dysfunction, male reproductive anomalies, and tubal patency issues. Approximately 15% of infertility cases are classified as "unexplained," highlighting the complexity of this condition. Lifestyle determinants such as obesity and smoking further complicate reproductive outcomes, while infertility can also indicate underlying chronic health conditions. A specialized category, immune infertility, arises from a breakdown of immunological tolerance, an essential aspect for conception and the maintenance of pregnancy. The role of various immunological components, including immune cells, cytokines, chemokines, factors like HLA-G, etc., is pivotal in this context. Moreover, non-coding RNAs (ncRNAs) have emerged as critical regulators of immune tolerance within the reproductive axis. This review synthesizes the complex immunological pathways vital for successful implantation and the early stages of pregnancy alongside the regulatory roles of ncRNAs in these processes. Offering an integrated view of molecular and immunological interactions associated with infertility seeks to enhance our understanding of potential strategies to facilitate successful conception and sustain early pregnancy.

项与 HLA-G 相关的新闻（医药）

2025-03-03

·PRNewswire

Biond Biologics to Regain Full Rights to BND-22, a Novel Immune Checkpoint Inhibitor Targeting the ILT2 Receptor

Following positive results from the Phase 1 dose escalation study, BND-22 (SAR444881) is now being tested in Phase 2 trials as monotherapy for patients with cholangiocarcinoma and in combination with cetuximab in patients with non-small cell lung cancer (NSCLC) and colorectal cancer (CRC). MISGAV, Israel, March 3, 2025 /PRNewswire/ -- Biond Biologics Ltd. ("Biond" or the "Company"), a private clinical-stage biopharmaceutical company developing novel therapies for cancer, today announced that it would regain full rights to BND-22 (SAR444881) from Sanofi. Sanofi is returning the rights of BND-22 as part of their broader R&D prioritization to focus on programs that support the company's strategy. Biond and Sanofi, are working together to complete full transfer of the BND-22 program to Biond. In January 2021, Biond entered into an exclusive worldwide license agreement with Sanofi for the development and commercialization of BND-22. As part of the agreement, Biond collaborated with Sanofi to initiate a first-in-human Phase 1 study (BND-22-001, NCT04717375), designed to evaluate the safety and tolerability of BND-22, both as a monotherapy and in combination with the approved cancer therapies cetuximab and pembrolizumab. The Phase 1 dose-escalation study was successfully completed and demonstrated a favorable safety profile across all patient groups. More specifically, data showed that BND-22 was well-tolerated and exhibited anti-tumor activity in heavily pretreated patients. Consistent with preclinical findings, a dose-dependent upregulation of activation markers was observed in monocytes and ILT2-expressing T and natural killer (NK) cell subsets. Notably, several confirmed clinical responses to both monotherapy and combination therapies regimens, were reported during the dose-escalation phase. These findings highlight the potential of BND-22 to address critical unmet needs in oncology. Building on these encouraging results, Sanofi initiated enrollment for a Phase 2 dose-optimization and expansion study (BND-22-001, NCT04717375). The study was designed to evaluate BND-22 as monotherapy for patients with cholangiocarcinoma and in combination with cetuximab for patients with non-small cell lung cancer (NSCLC) or colorectal cancer (CRC). For more information about the trial, please visit (Trial Identifier: NCT04717375). "As part of the agreement between Biond and Sanofi, Biond will regain full rights to BND-22, including access to the clinical data generated by Sanofi," said Dr. Tehila Ben Moshe, Biond's CEO and co-founder. "Sanofi has been an outstanding partner, and together, we have made remarkable progress in advancing the clinical development of BND-22. We remain committed to the continued development of BND-22 program, whether independently or in partnership with strategic collaborators". "We are encouraged by the data demonstrated so far for BND-22 in the dose-escalation and dose-expansion study", said Dr. Natalia Ashtamker, Biond's VP of Clinical Development. "We intend to continue treating patients who are benefiting from BND-22 treatment in the BND-22-001 study and are looking forward to the initiation of a Phase 2 biomarker study of BND-22 in combination with anti-PD-1 therapy". About BND-22 BND-22 is a humanized IgG4 antagonist antibody targeting the ILT2 receptor, developed for the treatment of solid tumors. ILT2 is an inhibitory immuno-modulating receptor expressed on both innate and adaptive immune cells. It binds to major histocompatibility complex (MHC) class I molecules, including HLA-G, an immunosuppressive protein expressed by various tumor types. Preclinical studies have demonstrated that BND-22 exerts broad anti-tumor effects by disrupting ILT2-mediated "do not eat me" signals in macrophages and activating NK and CD8+ lymphocytes. BND-22-001, a Phase 1/2 multicenter, open-label, dose-escalation, dose-expansion and dose optimization study enrolled patients with advanced solid tumors known to express HLA-G. The study included evaluations of BND-22 as monotherapy in cholangiocarcinoma and in combination with cetuximab in patients with non-small cell lung cancer (NSCLC) and colorectal cancer (CRC). Additionally, a future Phase 2 biomarker trial will explore BND-22 in combination with an anti-PD-1 agent in NSCLC, CRC and ovarian cancers. (Trial Identifier: NCT04717375). About Biond Biologics Biond Biologics is a drug discovery and development company focused on developing innovative therapies for novel oncology targets identified through research of immunoregulatory pathways. In parallel, it is developing a dedicated platform to facilitate the intracellular delivery of payloads, including biologics. Biond's clinical pipeline includes BND-22, a multi-cell checkpoint inhibitor targeting ILT2, and BND-35, a unique anti-ILT3/LILRB4 blocking antibody that drives the suppressive tumor microenvironment to become more pro-inflammatory. BND-35 also augments the Antibody dependent cellular cytotoxicity (ADCC) and Antibody dependent cellular phagocytosis (ADCP) activity of cancer-targeted therapies. BND-35 blocks the interaction between ILT3 and various ligands, including fibronectin, which can serve as a biomarker for patient selection. BND-35 entered a Phase 1 trial in May 2024. Biond is also developing BND-67, a first-in-class antibody, that specifically prevents the shedding of CD28 from T cells. Blocking CD28 shedding, drives prolonged T cell activation and enables safe and sustained immune responses. This unique approach can overcome resistance in patients treated with T cell-targeting therapies, such as anti-PD1/PDL1 blockers. BND-67 is expected to enter a phase 1 trial in 2026. In addition to its pipeline of immunotherapy agents, Biond is also developing INspire, a revolutionary platform that allows pH-specific delivery of various molecules, including biological drugs and small molecules into cancer cells. Biond was founded in 2016, by Tehila Ben Moshe, Ph.D., Ori Shilo, and a team of accomplished scientists and drug developers from the Israel biopharmaceutical industry. . Company contact: Tal Sines VP Business Development Biond Biologics Ltd. +972-4 884 4337 [email protected] SOURCE Biond Biologics Ltd. WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

临床1期引进/卖出免疫疗法临床2期临床结果

2025-02-05

·PRNewswire

China Medical University and Healthcare System Pioneers AI-Driven Drug Discovery and Allogeneic CAR-T Therapy: A Groundbreaking Leap in Cancer Treatment

TAICHUNG, Feb. 5, 2025 /PRNewswire/ -- Healthcare Expo Taiwan is a professional-oriented exposition involving healthcare, information/communication, technology, biopharmaceutical and medical device industries. Attended by healthcare professionals from all over the world, the Expo showcases the latest developments and trends in healthcare technology in Taiwan. China Medical University (CMU) and Healthcare System unveiled groundbreaking advancements in AI-driven drug discovery and cancer therapy at the latest 8th Healthcare Expo. These achievements cement CMU and Healthcare System's position as a global leader in healthcare innovation, setting new benchmarks for the biomedical industry. Continue Reading CMU and Healthcare System (Taiwan) highlights groundbreaking AI-driven drug discovery and unveils the latest advancements in healthcare innovations and their clinical applications. Dr. Chang-Hai Tsai, Chairman of CMU and Healthcare System, emphasized the institution's commitment to cutting-edge research and international collaboration. By partnering with Kyoto University, CMU and Healthcare System has established a global research center to spearhead advancements in cancer research, regenerative medicine, and AI-powered drug discovery. A Milestone in Cancer Therapy: Allogeneic CAR-T Achieves 90% Tumor Reduction CMU and Healthcare System revealed the world's first allogeneic CAR-T therapy for solid cancers, developed by Ever Supreme Bio Technology. This therapy has demonstrated an unprecedented tumor reduction rate of over 90% in pre-clinical studies. Human clinical trials are underway, with FDA approval marking a pivotal moment in solid tumor treatment. Precision Medicine Breakthroughs: Exosome Technology and AI Integration Shine-On Biomedical and Shine Out Bio Technology are revolutionizing precision medicine through exosome technology. Their innovations include: SOA101 Trispecific Antibody: A nanobody-based platform combining two immune checkpoint inhibitors, now in FDA-reviewed Phase I/IIa trials for cancer therapy. SOB100 HLA-G Targeted Exosome: Delivering drugs with pinpoint precision to tumors, this platform enhances efficacy while minimizing side effects. Human clinical trials for these technologies are set to begin in 2025, promising to transform cancer and neurodegenerative disease treatments. AI-Powered Healthcare Solutions CMU and Healthcare System's AI-driven initiatives include: Child Growth Assessment System: AI generates detailed diagnostic reports for personalized treatment planning. HiThings Tele-ICU: This state-of-the-art system integrates real-time patient data with 3D modeling for enhanced critical care management. Smart Health Scheduling: AI optimizes health examination processes to streamline care delivery. Computer-assisted detection platform for Tc-99mTRODAT-1: AI analyzes brain images and visual scales to assist in diagnosing central nervous system motor disorders. Long Term Care Record System and Medical Information Revise Assistant (MIRA): Enhances medical record accuracy and efficiency, allowing healthcare professionals to focus on patient care. Specialized Healthcare Innovations CMUH continues to lead in cutting-edge treatments: MRgFUS for Parkinson's Disease: A non-invasive, MRI-guided therapy offering new hope for patients. Proton Therapy Center: Delivering precision cancer treatments with reduced side effects. Gout Risk Prediction: Genetic testing for tailored patient management. Global Collaboration with Kyoto University The newly established CMU-Kyoto University Global Research Center strengthens ties in cancer research, translational medicine, and regenerative therapies. As part of this initiative, CMU Research Park integrates academic and industrial expertise to drive groundbreaking developments from laboratory research to clinical applications. Advancing Healthcare Through Innovation Dr. Der-Yang Cho, Superintendent of CMUH, highlighted AI's transformative role in drug discovery and clinical applications. CMU and Healthcare System remains at the forefront of healthcare innovation, bridging AI, biotechnology, and clinical practice to redefine the future of medicine. CMU and Healthcare System's pioneering work at the Healthcare Expo Taiwan underscores Taiwan's growing influence in global healthcare. With a focus on collaboration and innovation, CMU and Healthcare System is not just shaping the future of medicine—it's leading it. Contact Carolyn Chen [email protected] SOURCE China Medical University Hospital WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

临床研究

2025-01-13

·PRNewswire

CMU and Healthcare System Secures Unprecedented 17 Awards at the 2024 Taiwan National Innovation Awards

TAICHUNG, Jan. 12, 2025 /PRNewswire/ -- The Taiwan National Innovation Awards, regarded as the pinnacle of excellence in the biomedical and healthcare sectors, recognize the most transformative breakthroughs that push boundaries and redefine global standards. At the 21st annual awards in 2024, the China Medical University (CMU) and Healthcare System achieved an extraordinary milestone, sweeping 17 awards across three prestigious categories: two Corporate Innovation Awards, six Academic-Research Innovation Awards, and nine Clinical Innovation Awards. This unparalleled success cements CMU and Healthcare System's position as a trailblazer in biotechnology, smart healthcare, and innovative medical devices. Continue Reading At the 2024 Taiwan National Innovation Awards, CMU and Healthcare System achieved an extraordinary milestone, sweeping 17 awards through cell therapy, smart healthcare innovations, and exosome-based technology. A shining example of CMU and Healthcare System's innovative prowess is the groundbreaking CAR001 cell therapy developed by its spin-off, Ever Supreme Bio Technology. This revolutionary treatment employs allogeneic CAR and BiTE-GDT technologies to target solid tumors with unprecedented precision. Utilizing artificial intelligence, the research team identified HLA-G as a critical target for solid tumors, enabling the development of the CAR001 (CAR-T) technique. In preclinical animal trials, this breakthrough therapy achieved an astounding 90% tumor eradication rate, with results published in world-leading medical journals. The therapy has also received Phase I and IIa clinical trial approvals in both Taiwan and the United States, marking a pivotal step toward clinical application. Adding to the excitement, CMU and Healthcare System's innovations were showcased during the highly anticipated "Demo Day" segment of the awards. This platform features the most exceptional teams presenting their work to top Taiwanese investors for live evaluation and feedback. Ever Supreme Bio Technology stood out as one of the ten chosen teams, further underscoring the global potential and competitive edge of its technology. CMU and Healthcare System's achievements extend beyond cutting-edge therapies. Its pioneering use of artificial intelligence spans critical areas, including drug discovery, myocardial infarction treatment, infection and sepsis management, remote dialysis, image analysis, and medical education. Moreover, CMU and Healthcare System has redefined possibilities in exosome-based technology, offering transformative solutions for cancer and neurodegenerative diseases such as Parkinson's. The precision of its targeted exosome delivery system significantly enhances treatment outcomes, heralding new hope for patients with conditions once considered intractable. As a hub of innovation, CMU and Healthcare System exemplifies the synergy between research excellence and global collaboration. By forging partnerships with world-class academic and medical institutions, CMU and Healthcare System is accelerating the clinical adoption of groundbreaking technologies. Its unwavering commitment to advancing biomedical and smart healthcare innovation is transforming patient care and driving profound, lasting impact on the global stage. The future of healthcare has never looked brighter—and CMU and Healthcare System is at the forefront, leading the charge. Media contact: Carolyn Chen, [email protected] SOURCE China Medical University Hospital WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

临床1期细胞疗法临床结果